Advertisement

Commentary RE: Contemporary Update of Prostate Cancer Staging Nomograms (Partin Tables) for the New Millennium and Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005

  • Alan W. Partin
    Correspondence
    Address correspondence to: Alan W. Partin, M.D., Ph.D., The Brady Urological Institute, The Johns Hopkins Medical Institution, 600 N. Wolfe St., Marburg 134, Baltimore, MD 21287.
    Affiliations
    The Brady Urological Institute, The Johns Hopkins Medical Institution, 600 N. Wolfe St., Marburg 134, Baltimore,MD 21287
    Search for articles by this author
      In 1993, after spending time in the Urology clinic with several of our most prominent clinicians here at the Brady Urological Institute as a medical student, we thought that the answer to this frequent question [How does it look doc?] should be more analytical than “it looks pretty good.” Even in those times, every patient walked in with a Prostate Specific Antigen (PSA) value, a Gleason Score and we could complete a digital rectal exam to obtain Tumor, Node, Metastasis stage. In collaboration with our biostatistics, clinical chemistry and pathology colleagues, we created a “nomogram” which was designed to aid patients as well as physicians in making treatment decisions. Very soon after many patients began to refer to these nomograms as the “Partin Tables” for which I was greatly honored. These tables have been updated several times over the decades and published in JAMA, BJUI, and Urology. I am grateful to the residents, fellows and colleagues here at the Brady for all of the work that has gone into these updates.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Linked Article